Co-Diagnostics unit sends Ebola test kits to India lab for evaluation

Co-Diagnostics, Inc. (NASDAQ: CODX) announced that CoSara Diagnostics Pvt. Ltd., its joint venture in India, has sent 200 units of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for analytical studies, following a request from India's Centre for Cellular and Molecular Platforms (C-CAMP), an initiative supported by the India Department of Biotechnology.

The analytical studies are expected to evaluate the assay's limit of detection, repeatability, and reproducibility. C-CAMP's InDx 2.0 National Diagnostics Catapult, launched in 2023, aims to strengthen India's preparedness for current and future pandemics.

CoSara's Bundibugyo test was developed using Co-Diagnostics' patented Co-Primers technology and targets one of the Ebola virus species linked to current outbreaks in East and Central Africa. CoSara is also developing a second-generation pan-Ebola assay designed for broad-spectrum detection of Ebola species.

Co-Diagnostics also announced the completion of a proof-of-concept study for an extraction-free Co-Primers® Ebola test on its Co-Dx PCR Pro® instrument, using diluted plasma as a sample type. The company described this as the first blood-borne assay designed for use on the PCR Pro point-of-care instrument. The Co-Dx PCR platform has not yet received regulatory authorization and is not available for sale.

"The recent Ebola outbreak in Africa highlights the continued need for robust diagnostic preparedness and rapid public health response," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

You May Also Be Interested In

• YXT.com regains Nasdaq compliance after ADS ratio change
• Cousins Properties (CUZ) Tops Q2 EPS by 9c
• Karyopharm's endometrial cancer trial misses primary endpoint